Suscribirse

Personalized Activity Intelligence (PAI) for Prevention of Cardiovascular Disease and Promotion of Physical Activity - 18/04/17

Doi : 10.1016/j.amjmed.2016.09.031 
Bjarne M. Nes, PhD a, Christian R. Gutvik, PhD b, Carl J. Lavie, MD c, Javaid Nauman, PhD a, 1, , Ulrik Wisløff, PhD a, d, 1
a K.G. Jebsen Center of Exercise in Medicine at the Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Faculty of Medicine, Trondheim, Norway 
b Technology Transfer Office, Norwegian University of Science and Technology, Trondheim, Norway 
c Department of Cardiovascular Diseases, John Ochsner Heart and Vascular Institute, Ochsner Clinical School–University of Queensland School of Medicine, New Orleans, La 
d School of Human Movement & Nutrition Sciences, University of Queensland, St. Lucia, QLD, Australia 

Requests for reprints should be addressed to Javaid Nauman, PhD, K.G. Jebsen Center of Exercise in Medicine at the Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Medisinsk Teknisk Forskningssenter, Post Box 8905, 7491 Trondheim, Norway.K.G. Jebsen Center of Exercise in Medicine at the Department of Circulation and Medical ImagingNorwegian University of Science and TechnologyMedisinsk Teknisk Forskningssenter, Post Box 8905Trondheim7491Norway

Abstract

Purpose

To derive and validate a single metric of activity tracking that associates with lower risk of cardiovascular disease mortality.

Methods

We derived an algorithm, Personalized Activity Intelligence (PAI), using the HUNT Fitness Study (n = 4631), and validated it in the general HUNT population (n = 39,298) aged 20-74 years. The PAI was divided into three sex-specific groups (≤50, 51-99, and ≥100), and the inactive group (0 PAI) was used as the referent. Hazard ratios for all-cause and cardiovascular disease mortality were estimated using Cox proportional hazard regressions.

Results

After >1 million person-years of observations during a mean follow-up time of 26.2 (SD 5.9) years, there were 10,062 deaths, including 3867 deaths (2207 men and 1660 women) from cardiovascular disease. Men and women with a PAI level ≥100 had 17% (95% confidence interval [CI], 7%-27%) and 23% (95% CI, 4%-38%) reduced risk of cardiovascular disease mortality, respectively, compared with the inactive groups. Obtaining ≥100 PAI was associated with significantly lower risk for cardiovascular disease mortality in all prespecified age groups, and in participants with known cardiovascular disease risk factors (all P-trends <.01). Participants who did not obtain ≥100 PAI had increased risk of dying regardless of meeting the physical activity recommendations.

Conclusion

PAI may have a huge potential to motivate people to become and stay physically active, as it is an easily understandable and scientifically proven metric that could inform potential users of how much physical activity is needed to reduce the risk of premature cardiovascular disease death.

El texto completo de este artículo está disponible en PDF.

Keywords : Activity tracking, Cardiovascular disease mortality, Physical activity, Prevention


Esquema


 Funding: The authors are supported by grants from the K.G. Jebsen Foundation, Norwegian Research Council, and the Liaison Committee between the Central Norway Regional Health Authority and the Norwegian University of Science and Technology. The funding organisations had no role in the design and conduct of the study; in the collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
 Conflict of Interest: UW is a board member of Beatstack Inc, and has, together with Norwegian University of Science and Technology, shares in Mio Global that is developing an application that may utilize data from heart rate watches. There are no further disclosures to report and no conflicts of interest.
 Authorship: BMN, CRG, and JN had full access to all of the data in the study, analyzed the data, interpreted the results and wrote the paper. CJL and UW provided critical inputs and wrote the paper. All authors had access to the data and participated in writing the manuscript.


© 2016  The Authors. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 130 - N° 3

P. 328-336 - mars 2017 Regresar al número
Artículo precedente Artículo precedente
  • Trends in Incidence of Hospitalized Acute Myocardial Infarction in the Cardiovascular Research Network (CVRN)
  • Kristi Reynolds, Alan S. Go, Thomas K. Leong, Denise M. Boudreau, Andrea E. Cassidy-Bushrow, Stephen P. Fortmann, Robert J. Goldberg, Jerry H. Gurwitz, David J. Magid, Karen L. Margolis, Catherine J. McNeal, Katherine M. Newton, Rachel Novotny, Charles P. Quesenberry, Wayne D. Rosamond, David H. Smith, Jeffrey J. VanWormer, Suma Vupputuri, Stephen C. Waring, Marc S. Williams, Stephen Sidney
| Artículo siguiente Artículo siguiente
  • The Clinical Course of Venous Thromboembolism May Differ According to Cancer Site
  • Isabelle Mahé, Jean Chidiac, Laurent Bertoletti, Carme Font, Javier Trujillo-Santos, Marisa Peris, Cristina Pérez Ductor, Santiago Nieto, Elvira Grandone, Manuel Monreal

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.